# EDGAR Filing Document

**Accession Number:** 0001849296
**File Stem:** 0001493152-23-009375
**Filing Date:** 2023-3
**Character Count:** 6979
**Document Hash:** 2cf4118614818e055c8f471389cbf456
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-009375.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001493152-23-009375

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230329

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OKYO Pharma Ltd
- **CENTRAL INDEX KEY:** 0001849296
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41386
- **FILM NUMBER:** 23771713

**BUSINESS ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA
- **BUSINESS PHONE:** 44 (0) 207 495 2379

**MAIL ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**March 2023**

------

**Commission File Number:** 001-41386

------

**OKYO Pharma LTD**

(Exact Name of Registrant as Specified in Its Charter)

------

**9<sup>th</sup> Floor**

**107 Cheapside**

**London**

**EC2V 6DN**

(Address of registrant's principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On March 29, 2023, OKYO Pharma LTD (the "<u>Company</u>") issued this 6K announcing that, it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 12,500 of the Company's ADSs on NASDAQ at a price of US$1.32 per ADS, a copy of which is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **OKYO Pharma LTD** | **OKYO Pharma LTD** |
| Date: March 29 2023 | By: | */s/ Keeren Shah* |
|  | Name: | Keeren Shah |
|  | Title: | Chief Financial Officer |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [News Announcement, dated March 29, 2023](ex99-1.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

**Director acquires shares**

**London and New York, NY, 29 March, 2023** – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ("DED") to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 12,500 of the Company's ADSs on NASDAQ at a price of US$1.32 per ADS (which would be equivalent to the purchase of 812,500 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0165 each).

---

| | | |
|:---|:---|:---|
| 1. | Details of PDMR / person closely associated | Details of PDMR / person closely associated |
| a) | Name | Gabriele Cerrone |
| 2. | Reason for the notification | Reason for the notification |
| a) | Position / status | Chairman |
| b) | Initial notification /amendment | Initial notification |
| 3. | Details of the issuer | Details of the issuer |
| a) | Name | OKYO Pharma Limited |
| b) | LEI | 213800VVN5CB56Y15A05 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| a) | Description of the financial instrument | ADSs representing 65 Ordinary Shares of no par value |
| b) | Identification code of the Financial Instrument | ISIN for OKYO Pharma Limited GG00BD3FV870 |

---

---

| | | |
|:---|:---|:---|
| c) | Nature of the transaction | Market Purchase |
| d) | Price(s) and volume(s) | $1.32 - 12500<br>|
| f) | Date of the transaction | 27 March 2023 |
| g) | Place of the transaction | NASDAQ |

---

***Enquiries:***

 ****

---

| | | |
|:---|:---|:---|
| ***OKYO Pharma Limited*** | *Gary S. Jacob, Chief Executive Officer*<br>| *+44 (0)20 7495 2379*<br>|
| ***Investor Relations*** | *Paul Spencer* | *+44 (0)20 7495 2379* |
| ***Broker***<br>| *Robert Emmet, Optiva Securities Limited*<br>| *+44 (0)20 3981 4173* |

---

***Notes for Editors:***

 

**About OKYO**

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit <u>www.okyopharma.com</u>.

**About OK-101**

OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.